Erick Lucera - 02 Mar 2024 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role: EVP, CHIEF FINANCIAL OFFICER
Signature: /s/ Erick Lucera
Issuer symbol: EDIT
Transactions as of: 02 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Mar 2024, 20:06:54 UTC
Previous filing: 20 Sep 2023
Next filing: 21 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EDIT	Common Stock	Award	$0	+35,300	+45%	$0.000000	113,200	02 Mar 2024	Direct	F1
transaction	EDIT	Common Stock	Award	$0	+25,966	+23%	$0.000000	139,166	02 Mar 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EDIT	Stock Option (right to buy)	Award	$0	+106,000		$0.000000	106,000	02 Mar 2024	Common Stock	106,000	$10.53	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
F2	Reflects the acquisition, upon the achievement of a specified business development milestone, of a portion of a performance-based restricted stock unit award originally granted on May 17, 2023. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on May 17, 2024, subject to continued service.
F3	This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.